PhaseBio Pharmaceuticals Receivables

Receivables of PHAS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Receivables growth rates and interactive chart. Accounts receivable (AR) is the balance of money due to a firm for goods or services delivered or used but not yet paid for by customers. Accounts receivables are listed on the balance sheet as a current asset. AR is any amount of money owed by customers for purchases made on credit. When a company makes a sale, it records revenues and a corresponding balance in accounts receivable. When an invoice is paid, the accounts payable account is reduced and cash is received. Receivables should grow in-line with revenue over time, if they are growing much faster, a company might be booking revenue too aggressively.


Highlights and Quick Summary

  • Receivables for the quarter ending June 30, 2021 was $18.4 Million (a 1953.57% increase compared to previous quarter)
  • Year-over-year quarterly Receivables increased by 3056.09%
  • Annual Receivables for 2019 was $1.23 Million (a 429.18% increase from previous year)
Visit stockrow.com/PHAS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Receivables of PhaseBio Pharmaceuticals

Most recent Receivablesof PHAS including historical data for past 10 years.

Interactive Chart of Receivables of PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals Receivables for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $18.4
2020 $0.9
2019 $1.23 $0.58 $1.18 $0.67 $1.23
2018 $0.23 $0.41 $0.23

Business Profile of PhaseBio Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology